MedTrace Logo

Antidepressant Response of DMT Masked With Propofol

NCT06927076 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2026-04-02

No results posted yet for this study

Summary

The aim of this study is to elucidate if the anti-depressive effect of N,N-dimethyltryptamine (DMT) is based on a biological mechanisms including neuroplasticity and anti-inflammatory effect or due to the subjective psychedelic experience.

Conditions

Interventions

DRUG

N,N-Dimethyltryptamine

administration of a 2mg/min DMT perfusion over 20 min

DRUG

Placebo

administration of a placebo perfusion over 20 min

PROCEDURE

Propofol

30 min propofol sedation

PROCEDURE

no sedation

no sedation

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Matthias Liechti, Prof. Dr. med. · University Hospital, Basel, Switzerland

  • Felix Müller, PD Dr. med. · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-05
Primary Completion
2029-03-31
Completion
2029-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06927076 on ClinicalTrials.gov